Policy & funding

• Enacted 2026
• Effective 2026
• $900,000

BOLD Public Health Centers of Excellence / national partner (CDC-RFA-DP20-2005 or DP-26-0227). Period of performance 2026-09-30 to 2031-09-29. USAspending description: COMPONENT 3: ADRD PUBLIC HEALTH ADOPTION ACCELERATOR - NORC AT THE UNIVERSITY OF CHICAGO, IN PARTNERSHIP WITH BURNESS, THE ALZHEIMER’S ASSOCIATION, USAGING, AND THE NATIONAL RURAL HEALTH ASSOCIATION (NRHA), WILL ESTABLIS

Who it covers: Jurisdiction served by National Opinion Research Center (MD)

The dollar value = USAspending 'Award Amount' = total obligated to date on the award as of 2026-09-22, NOT the annual amount and NOT the full 5-year ceiling; FY breakdown not captured. CFDA 93.283.

Source: USAspending.gov API v2 spending_by_award (CDC assistance awards); CDC BOLD recipient list for cohort membership

• Enacted 2026
• Effective 2026
• $906,241

BOLD Public Health Centers of Excellence / national partner (CDC-RFA-DP20-2005 or DP-26-0227). Period of performance 2026-09-30 to 2031-09-29. USAspending description: PUBLIC HEALTH CENTER OF EXCELLENCE ON DEMENTIA CAREGIVING WILL EXPAND ITS DISSEMINATION AND ENGAGEMENT TO PROFESSIONALS TO ADVANCE THE NATION'S PUBLIC HEALTH RESPONSE TO CAREGIVING. - THERE ARE 12.7 MILLION UNPAID INDIV

Who it covers: Jurisdiction served by Regents Of The University Of Minnesota (MN)

The dollar value = USAspending 'Award Amount' = total obligated to date on the award as of 2026-09-22, NOT the annual amount and NOT the full 5-year ceiling; FY breakdown not captured. CFDA 93.283.

Source: USAspending.gov API v2 spending_by_award (CDC assistance awards); CDC BOLD recipient list for cohort membership

• Enacted 2026
• Effective 2026
• $900,000

BOLD Public Health Centers of Excellence / national partner (CDC-RFA-DP20-2005 or DP-26-0227). Period of performance 2026-09-30 to 2031-09-29. USAspending description: HEALTHY BRAIN IMPACT INITIATIVE: ACCELERATING ADOPTION OF EVIDENCE-BASED ADRD STRATEGIES. - ALZHEIMER’S DISEASE AND RELATED DEMENTIAS (ADRD) ARE A GROWING PUBLIC HEALTH CHALLENGE, MARKED BY RISING PREVALENCE, GEOGRAPHIC

Who it covers: Jurisdiction served by National Association Of Community Health Centers, Inc. (MD)

The dollar value = USAspending 'Award Amount' = total obligated to date on the award as of 2026-09-22, NOT the annual amount and NOT the full 5-year ceiling; FY breakdown not captured. CFDA 93.283.

Source: USAspending.gov API v2 spending_by_award (CDC assistance awards); CDC BOLD recipient list for cohort membership

• Enacted 2026
• Effective 2026
• $3,000,000

BOLD Public Health Centers of Excellence / national partner (CDC-RFA-DP20-2005 or DP-26-0227). Period of performance 2026-09-30 to 2031-09-29. USAspending description: CDC-RFA-DP-26-0227 COMPONENT 1 ? NATIONAL HEALTHY BRAIN INITIATIVE- ALZHEIMER?S ASSOCIATION - CDC-RFA-DP-26-0227 COMPONENT 1 – NATIONAL HEALTHY BRAIN INITIATIVE- ALZHEIMER’S ASSOCIATION

Who it covers: Jurisdiction served by Alzheimers Disease & Related Disorders Association Inc (IL)

The dollar value = USAspending 'Award Amount' = total obligated to date on the award as of 2026-09-22, NOT the annual amount and NOT the full 5-year ceiling; FY breakdown not captured. CFDA 93.283.

Source: USAspending.gov API v2 spending_by_award (CDC assistance awards); CDC BOLD recipient list for cohort membership

• Enacted 2026
• Effective 2026
• $1,000,000

BOLD Public Health Centers of Excellence / national partner (CDC-RFA-DP20-2005 or DP-26-0227). Period of performance 2026-09-30 to 2031-09-29. USAspending description: PUBLIC HEALTH CENTER OF EXCELLENCE ON DEMENTIA RISK REDUCTION - ALZHEIMER'S DISEASE AND RELATED DEMENTIAS (ADRD) AFFECT MORE THAN 7 MILLION AMERICANS AND ARE PROJECTED TO IMPACT 13 MILLION BY 2060, AT AN ESTIMATED COST O

Who it covers: Jurisdiction served by Alzheimers Disease & Related Disorders Association Inc (IL)

The dollar value = USAspending 'Award Amount' = total obligated to date on the award as of 2026-09-22, NOT the annual amount and NOT the full 5-year ceiling; FY breakdown not captured. CFDA 93.283.

Source: USAspending.gov API v2 spending_by_award (CDC assistance awards); CDC BOLD recipient list for cohort membership

• Enacted 2026
• Effective 2026
• $900,000

BOLD Public Health Centers of Excellence / national partner (CDC-RFA-DP20-2005 or DP-26-0227). Period of performance 2026-09-30 to 2031-09-29. USAspending description: TRIBAL BRAIN HEALTH PUBLIC HEALTH ADOPTION ACCELERATOR, COMPONENT 3 - ALZHEIMER’S DISEASE AND RELATED DEMENTIAS (ADRD) REPRESENT ONE OF THE NATION’S MOST SIGNIFICANT PUBLIC HEALTH CHALLENGES. ALTHOUGH SUBSTANTIAL PROGRES

Who it covers: Jurisdiction served by Great Lakes Inter-Tribal Council, Inc. (WI)

The dollar value = USAspending 'Award Amount' = total obligated to date on the award as of 2026-09-22, NOT the annual amount and NOT the full 5-year ceiling; FY breakdown not captured. CFDA 93.283.

Source: USAspending.gov API v2 spending_by_award (CDC assistance awards); CDC BOLD recipient list for cohort membership

• Enacted 2024
• Effective 2024

Extends the National Alzheimer's Project through 2035, adds a focus on promoting healthy aging and reducing risk factors for cognitive decline, and expands the Advisory Council (adds a clinical-trial diversity researcher, an individual diagnosed with Alzheimer's, and representatives of additional federal agencies such as the Department of Justice).

Who it covers: US population with AD/ADRD

Sponsor Sen. Susan Collins; introduced 2023-01-30; 44 cosponsors; latest action 2024-10-01 'Became Public Law No: 118-92'. The task brief called this the 'ACHIEVE/NAPA Reauthorization Act'; no bill titled 'ACHIEVE Act' could be found on congress.gov or alzimpact.org, so only the NAPA Reauthorization Act is recorded.

Source: Congress.gov bill page and API (CRS public-law summary dated 2024-10-02)

• Enacted 2024
• Effective 2024

Requires NIH, beginning FY2024, to annually submit an estimate of its budget and personnel needs for carrying out National Alzheimer's Project initiatives (the 'professional judgment budget') directly to the President for transmittal to Congress; HHS and the Advisory Council may comment but not change it. Reauthorizes the 2014 Alzheimer's Accountability Act mechanism.

Who it covers: NIH Alzheimer's research enterprise

Introduced 2023-01-30; latest action 2024-10-01 'Became Public Law No: 118-93'.

Source: Congress.gov API (CRS public-law summary dated 2024-10-02)

• Enacted 2024
• Effective 2025

Reauthorizes the 2018 BOLD Infrastructure for Alzheimer's Act (P.L. 115-406), which was set to expire after FY2024, so CDC can continue funding public health departments and the ADRD Public Health Centers of Excellence.

Who it covers: State, local, tribal and territorial public health departments (US)

Sponsor Rep. Brett Guthrie; introduced 2024-02-05; 79 cosponsors; reported by Energy and Commerce 2024-05-21 (H. Rept. 118-515); latest action 2024-12-11 'Became Public Law No: 118-142'. Senate companion S.3775. Alzheimer's Association press release (2024-09-17) records the unanimous House passage. Authorization amounts not captured (statute text not read).

Source: Congress.gov bill page

• Enacted 2024
• Effective 2024

CMS's GUIDE participant list (xlsx, 'Last updated August 2026') contains 474 GUIDE IDs; each lists the state(s) in which it provides services (participants may serve multiple states or serve virtually). Count of participants listing each state: AK 27, AL 27, AR 39, AZ 45, CA 70, CO 36, CT 50, DC 19, DE 35, FL 88, GA 58, HI 28, IA 55, ID 33, IL 50, IN 49, KS 26, KY 55, LA 26, MA 38, MD 46, ME 16, MI 45, MN 37, MO 41, MS 37, MT 23, NC 62, ND 18, NE 26, NH 25, NJ 65, NM 37, NV 34, NY 83, OH 64, OK 30, OR 44, PA 121, RI 20, SC 54, SD 24, TN 47, TX 69, UT 42, VA 66, VT 27, WA 39, WI 49, WV 29, WY 36; territories AS 8, GU 1, MP 1, FM 1, MH 2; 'Not available' 20.

Who it covers: Medicare beneficiaries with dementia in the states served by 474 listed GUIDE participants

(count of rows in CMS's own list, computed 2026-09-22 by splitting the 'State(s) in which Participant Provides Services' column on ';'). Counts sum to more than 474 because many participants list several states. NOTE: the GUIDE web page shows 'Number of Participants: 292' while the August 2026 xlsx has 474 GUIDE IDs; the discrepancy is CMS's and is left unresolved here.

Source: CMS Innovation Center, GUIDE Providers (Participant List) xlsx

• Enacted 2023
• Effective 2024
• $2,500

Voluntary nationwide 8-year model that began July 1, 2024. Pays Medicare Part B providers/suppliers that run dementia care programs for comprehensive care coordination and care management, caregiver education and support, 24/7 support line, care navigation, screening for health-related social needs, and respite services reimbursed up to $2,500 per eligible patient per year. Established Program Track began delivering services 2024-07-01; New Program Track completed a pre-implementation year and began 2025-07-01.

Who it covers: Medicare fee-for-service beneficiaries with dementia and their unpaid caregivers, served by 292 participant dementia care programs

/PROGRAM RULE. The dollar value = the annual per-patient respite services cap ($2,500) stated on the page; it is not a program budget. 'Number of Participants: 292' is as displayed on the page on 2026-09-22. The year given 2023 = year the model was announced (the page says the model 'began on July 1, 2024'; announcement year is from CMS's model timeline and should be treated as approximate).

Source: CMS Innovation Center GUIDE Model page

• Enacted 2023
• Effective 2023

Final decision dated October 13, 2023 removed the 2013 NCD that had limited amyloid PET to one scan per patient under coverage with evidence development. Coverage decisions for amyloid PET are now made by Medicare Administrative Contractors under Section 1862(a)(1)(A), which may cover more than one scan per patient (e.g., for anti-amyloid treatment eligibility and monitoring). Proposed decision was posted July 17, 2023.

Who it covers: Medicare beneficiaries being evaluated for Alzheimer's disease (amyloid PET)

/COVERAGE RULE. Status 'repealed' refers to the NCD (the original 2013 CED NCD, effective 2013-09-27, was removed); the effect is broader coverage, not less. CMS declined to make the decision retroactive.

Source: CMS Medicare Coverage Database, final decision memorandum CAG-00431R

• Enacted 2023
• Effective 2023

CDC-Alzheimer's Association public health action framework; fourth edition covers 2023-2027 with four domains, greater emphasis on partnerships and health equity, and input from 100+ experts. A companion Road Map for American Indian and Alaska Native Peoples exists. CDC states Congress first appropriated funds for CDC brain-health/dementia work in 2005, which led to the Road Map series; BOLD Public Health Program recipients implement Road Map actions.

Who it covers: US state, local and tribal public health agencies; people with ADRD and caregivers

/PROGRAM DOCUMENT. Edition years and 2005 origin as stated on the CDC page read 2026-09-22; earlier edition years (1st-3rd) are not given on the page and are not recorded. No dollar figure on the page.

Source: CDC National Healthy Brain Initiative pages (index and Road Map page)

• Enacted 2022
• Effective 2022

Effective April 7, 2022, Medicare covers FDA-approved anti-amyloid monoclonal antibodies under coverage with evidence development (CED). Antibodies approved on a surrogate endpoint (amyloid reduction) are covered only in randomized controlled trials; antibodies approved on a direct measure of clinical benefit (e.g., lecanemab, donanemab) are covered in CMS-approved prospective comparative studies including registries, and in NIH-supported trials. Amyloid PET performed under an approved study protocol also satisfied the amyloid PET CED requirement.

Who it covers: Medicare beneficiaries with a clinical diagnosis of MCI due to AD or mild AD dementia with confirmed amyloid pathology

/COVERAGE RULE. Registry-based coverage for traditionally approved drugs has been operating since the July 2023 lecanemab traditional approval (see our cost data coverage rows for VA and CMS context). NCD decision memo is CAG-00460N (ncaid=305).

Source: CMS Medicare Coverage Database, NCD 200.3

• Enacted 2020
• Effective 2020
• $3,392,610

BOLD Public Health Centers of Excellence / national partner (CDC-RFA-DP20-2005 or DP-26-0227). Period of performance 2020-09-30 to 2026-09-29. USAspending description: THE PUBLIC HEALTH CENTER OF EXCELLENCE ON DEMENTIA CAREGIVING

Who it covers: Jurisdiction served by Regents Of The University Of Minnesota (MN)

The dollar value = USAspending 'Award Amount' = total obligated to date on the award as of 2026-09-22, NOT the annual amount and NOT the full 5-year ceiling; FY breakdown not captured. CFDA 93.283.

Source: USAspending.gov API v2 spending_by_award (CDC assistance awards); CDC BOLD recipient list for cohort membership

• Enacted 2020
• Effective 2020
• $3,486,856

BOLD Public Health Centers of Excellence / national partner (CDC-RFA-DP20-2005 or DP-26-0227). Period of performance 2020-09-30 to 2026-09-29. USAspending description: NYU BOLD PUBLIC HEALTH CENTER OF EXCELLENCE ON EARLY DETECTION OF DEMENTIA

Who it covers: Jurisdiction served by New York University (NY)

The dollar value = USAspending 'Award Amount' = total obligated to date on the award as of 2026-09-22, NOT the annual amount and NOT the full 5-year ceiling; FY breakdown not captured. CFDA 93.283.

Source: USAspending.gov API v2 spending_by_award (CDC assistance awards); CDC BOLD recipient list for cohort membership

• Enacted 2020
• Effective 2020
• $4,440,922

BOLD Public Health Centers of Excellence / national partner (CDC-RFA-DP20-2005 or DP-26-0227). Period of performance 2020-09-30 to 2026-09-29. USAspending description: DEMENTIA RISK REDUCTION PUBLIC HEALTH CENTER OF EXCELLENCE

Who it covers: Jurisdiction served by Alzheimers Disease & Related Disorders Association Inc (IL)

The dollar value = USAspending 'Award Amount' = total obligated to date on the award as of 2026-09-22, NOT the annual amount and NOT the full 5-year ceiling; FY breakdown not captured. CFDA 93.283.

Source: USAspending.gov API v2 spending_by_award (CDC assistance awards); CDC BOLD recipient list for cohort membership

• Enacted 2020
• Effective 2020

Section 202 amends the Older Americans Act (sections 302(3) and 711(6)) by inserting 'of any age' so that individuals with Alzheimer's disease and related disorders who are younger than 60 become eligible for OAA supportive services and family caregiver support programs. The stand-alone Younger Onset Alzheimer's Disease Act (S.901, Sen. Collins, introduced 2019-03-27) was folded into this reauthorization.

Who it covers: US individuals with Alzheimer's disease of any age (extends Older Americans Act supportive services and National Family Caregiver Support Program eligibility below age 60)

H.R.4334 sponsor Rep. Suzanne Bonamici; introduced 2019-09-16; latest action 2020-03-25 'Became Public Law No: 116-131'. Sec. 202 text read directly from the enrolled law. The same law authorizes OAA Title III appropriations FY2020-FY2024 (e.g. Supportive services $412,029,180 for FY2020) but those are not dementia-specific so the dollar value is left empty.

Source: GovInfo enrolled public-law text (PLAW-116publ131) and GovInfo BILLSTATUS XML for H.R.4334 and S.901

• Enacted 2018
• Effective 2019

Directs CDC to establish Alzheimer's Disease and Related Dementias Public Health Centers of Excellence, fund public health departments to implement the Healthy Brain Initiative Road Map, and increase data analysis and timely reporting on Alzheimer's, cognitive decline, caregiving and health disparities. Focus areas: dementia risk reduction, early detection and diagnosis, prevention of avoidable hospitalizations, dementia caregiving.

Who it covers: State, local, tribal and territorial public health departments (US)

Congress.gov API: introduced 2017-11-06, latest action 2018-12-31 'Became Public Law No: 115-406'. Annual authorization amount not captured (bill text not read); see the per-fiscal-year BOLD appropriation rows for enacted dollars.

Source: CDC Alzheimer's Disease Program: BOLD Infrastructure for Alzheimer's Act page (updated 2024-06-25) and Congress.gov API bill record

• Enacted 2018
• Effective 2018

Directs HHS to develop and publish a National Family Caregiving Strategy identifying recommended actions for recognizing and supporting family caregivers, and to convene a Family Caregiving Advisory Council; the council terminates after three years under the enacted text.

Who it covers: US family caregivers (all conditions, including dementia caregivers)

Sponsor Rep. Gregg Harper; introduced 2017-09-13; latest action 2018-01-22 'Became Public Law No: 115-119'. Senate companion S.1028 (Sen. Collins) passed the Senate 2017-09-26 but the House bill was the enacted vehicle. Not dementia-specific; included because dementia caregivers are the largest population addressed by the resulting strategy. No dollar authorization in the CRS summary.

Source: GovInfo BILLSTATUS bulk XML (H.R.3759, 115th Congress) with CRS public-law summary

• Enacted 2012
• Effective 2012

HHS strategic plan required by NAPA, first released May 2012 and updated annually (updates listed on ASPE for 2013 through 2024). Six goals: (1) Prevent and effectively treat AD/ADRD by 2025; (2) Enhance care quality and efficiency; (3) Expand supports for people with AD/ADRD and their families; (4) Enhance public awareness and engagement; (5) Improve data to track progress; (6, added 2021) Accelerate action to promote healthy aging and reduce risk factors for AD/ADRD.

Who it covers: US population with AD/ADRD and their families

Goal-1 target year 2025 is the plan's headline 'annual target'. ASPE page carries a banner that content is not being updated during HHS restructuring; the most recent update listed is the 2024 Update. The May/June 2012 first-plan date comes from the page's '10th Anniversary ... May and June 2022' statement.

Source: ASPE (HHS) National Plan to Address Alzheimer's Disease page (read via Wayback Machine 2025 snapshot; live page returns HTTP 403)

• Enacted 2011
• Effective 2011

Establishes the National Alzheimer's Project in the Office of the HHS Secretary; requires an integrated national plan to overcome Alzheimer's, coordination of federal research and services, acceleration of treatments, improved early diagnosis and care coordination, inclusion of higher-risk ethnic/racial populations, and international coordination. Creates the Advisory Council on Alzheimer's Research, Care, and Services with an annually updated national plan. Original sunset for the Project and the Council: December 31, 2025 (later extended to 2035 by P.L. 118-92).

Who it covers: US population with Alzheimer's disease and related dementias (AD/ADRD)

Introduced 2010-02-24 (Sen.); latest action 2011-01-04 'Became Public Law No: 111-375'. Summary text is the CRS public-law summary dated 2011-01-04. No dollar authorization figure in the CRS summary.

Source: Congress.gov API (bill record and CRS summary), Library of Congress

Would create a pathway for Medicare coverage of blood-based Alzheimer's/dementia screening tests through Medicare's evidence-based coverage process (modelled on the MCED Act approach for cancer screening), removing the statutory bar on Medicare coverage of screening tests for diseases that cause dementia. NOT enacted as of 2026-09-22.

Who it covers: Medicare beneficiaries (proposed coverage pathway for blood-based dementia screening tests)

/STATUS. H.R.6130: introduced 2025-11-19 by Rep. Vern Buchanan (R-FL-16), 219 cosponsors in the XML, referred to Energy and Commerce and Ways and Means; latest action 2026-09-16 Ways and Means 'Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 40 - 0'. S.3267: introduced 2025-11-20 by Sen. Susan Collins, 49 cosponsors, referred to Senate Finance (no further Senate action in XML). AIM press release 2026-09-16 cites 217 House / 50 Senate cosponsors. Congress.gov HTML pages for these two bills were Cloudflare-blocked, so status is from GovInfo XML.

Source: GovInfo BILLSTATUS bulk XML (H.R.6130 and S.3267, 119th Congress); alzimpact.org ASAP Act page and 2026-09-16 AIM press release

Would provide grants to primary care providers participating in structured virtual Alzheimer's and dementia education programs to improve diagnosis and community-based dementia care. Passed the House in July 2026; pending in Senate HELP. NOT enacted as of 2026-09-22.

Who it covers: Primary care providers (US)

/STATUS. H.R.3747: sponsor Rep. Troy Balderson (R-OH-12), introduced 2025-06-05, 97 cosponsors, reported (amended) by Energy and Commerce 2026-07-02 (H. Rept. 119-723); latest action 2026-07-21 'Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions'. S.4036: sponsor Sen. Shelley Moore Capito, introduced 2026-03-10, 9 cosponsors, referred to HELP. Grant dollar amounts not captured.

Source: Congress.gov bill pages (H.R.3747, S.4036); alzimpact.org AADAPT page

House bill on early detection of Alzheimer's disease introduced 2026-07-22 and referred to the Committee on Energy and Commerce; no further action recorded. NOT enacted.

Who it covers: US (bill scope not read)

/STATUS. Sponsor Rep. Jake Auchincloss (D-MA-4); 2 cosponsors. Bill text and CRS summary not available in the XML at time of fetch, so the policy type 'coverage' is inferred from the title only.

Source: GovInfo BILLSTATUS bulk XML

Medicare covers a separate visit to assess cognitive function and develop a written care plan when cognitive impairment is detected at an Annual Wellness Visit (HCPCS G0438/G0439, which require checking for cognitive impairment) or other routine visit; billed with CPT 99483, typically 60 minutes face-to-face with an independent historian present, covering functional assessment, dementia staging (FAST, CDR), medication review, neuropsychiatric screening, safety evaluation, caregiver supports, and advance care planning; may be furnished via telehealth.

Who it covers: Medicare beneficiaries showing signs of cognitive impairment

/PROGRAM RULE. The CMS page does not state when the code took effect, so year fields are left empty rather than asserted (the 99483 code and its predecessor G0505 pre-date this page). Page read via r.jina.ai on 2026-09-22. No payment rate is given on the page.

Source: CMS 'Cognitive Assessment & Care Plan Services' provider page (page last modified 2026-05-20)